Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02949011
Registration number
NCT02949011
Ethics application status
Date submitted
27/10/2016
Date registered
31/10/2016
Date last updated
19/11/2019
Titles & IDs
Public title
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
Query!
Secondary ID [1]
0
0
2016-002688-32
Query!
Secondary ID [2]
0
0
1602T0832
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CAPSTONE 2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Influenza
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Baloxavir Marboxil
Treatment: Drugs - Placebo to Baloxavir Marboxil
Treatment: Drugs - Oseltamivir
Treatment: Drugs - Placebo to Oseltamivir
Experimental: Baloxavir Marboxil - Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or = 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Active Comparator: Oseltamivir - Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
Placebo Comparator: Placebo - Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
Treatment: Drugs: Baloxavir Marboxil
Tablets taken orally
Treatment: Drugs: Placebo to Baloxavir Marboxil
Matching tablets taken orally
Treatment: Drugs: Oseltamivir
Capsules taken orally
Treatment: Drugs: Placebo to Oseltamivir
Matching placebo capsules taken orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to Improvement of Influenza Symptoms
Query!
Assessment method [1]
0
0
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.
Query!
Timepoint [1]
0
0
From Day 1 pretreatment up to Day 14
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point
Query!
Assessment method [1]
0
0
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log10 of the 50% tissue culture infective dose (TCID50/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.
Query!
Timepoint [1]
0
0
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point
Query!
Assessment method [2]
0
0
Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log10 virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.
Query!
Timepoint [2]
0
0
Days 2, 3, 4 (optional), 5, 6 (optional), and 9.
Query!
Secondary outcome [3]
0
0
Change From Baseline in Virus Titer at Each Time Point
Query!
Assessment method [3]
0
0
Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID50/mL).
Query!
Timepoint [3]
0
0
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Query!
Secondary outcome [4]
0
0
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point
Query!
Assessment method [4]
0
0
Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
Query!
Timepoint [4]
0
0
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Query!
Secondary outcome [5]
0
0
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer
Query!
Assessment method [5]
0
0
This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
Query!
Timepoint [5]
0
0
Day 1 to Day 9
Query!
Secondary outcome [6]
0
0
Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA
Query!
Assessment method [6]
0
0
This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
Query!
Timepoint [6]
0
0
Day 1 to Day 9
Query!
Secondary outcome [7]
0
0
Time to Cessation of Viral Shedding Determined by Virus Titer
Query!
Assessment method [7]
0
0
Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log10[TCID50/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
Query!
Timepoint [7]
0
0
Day 1 to Day 9
Query!
Secondary outcome [8]
0
0
Time to Cessation of Viral Shedding Determined by Virus RNA
Query!
Assessment method [8]
0
0
Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
Query!
Timepoint [8]
0
0
Day 1 to Day 9
Query!
Secondary outcome [9]
0
0
Percentage of Participants Whose Symptoms Were Improved at Each Time Point
Query!
Assessment method [9]
0
0
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe).
Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity
Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Query!
Timepoint [9]
0
0
12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Query!
Secondary outcome [10]
0
0
Time to Alleviation of Symptoms
Query!
Assessment method [10]
0
0
Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
Query!
Timepoint [10]
0
0
Initiation of study treatment up to Day 14
Query!
Secondary outcome [11]
0
0
Time to Improvement of the Four Systemic Symptoms
Query!
Assessment method [11]
0
0
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.
Query!
Timepoint [11]
0
0
Initiation of study treatment up to Day 14
Query!
Secondary outcome [12]
0
0
Time to Improvement of the Three Respiratory Symptoms
Query!
Assessment method [12]
0
0
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.
Query!
Timepoint [12]
0
0
Initiation of study treatment up to Day 14
Query!
Secondary outcome [13]
0
0
Time to Resolution of Fever
Query!
Assessment method [13]
0
0
Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
Query!
Timepoint [13]
0
0
Initiation of study treatment up to Day 14
Query!
Secondary outcome [14]
0
0
Percentage of Participants Reporting Normal Temperature at Each Time Point
Query!
Assessment method [14]
0
0
Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.
Query!
Timepoint [14]
0
0
12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Query!
Secondary outcome [15]
0
0
Body Temperature at Each Time Point
Query!
Assessment method [15]
0
0
Participant's self-measured axillary temperature using an electronic thermometer.
Query!
Timepoint [15]
0
0
12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Query!
Secondary outcome [16]
0
0
Time to Improvement of Individual Symptoms
Query!
Assessment method [16]
0
0
Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours:
Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline
Preexisting symptoms not worse at baseline must have maintained baseline severity
New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours.
Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.
Query!
Timepoint [16]
0
0
Initiation of study treatment up to Day 14
Query!
Secondary outcome [17]
0
0
Time to Return to Preinfluenza Health Status
Query!
Assessment method [17]
0
0
Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and condition]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
Query!
Timepoint [17]
0
0
Baseline to Day 14
Query!
Secondary outcome [18]
0
0
Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection
Query!
Assessment method [18]
0
0
The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).
Query!
Timepoint [18]
0
0
Day 2 to Day 22
Query!
Secondary outcome [19]
0
0
Percentage of Participants With Influenza-related Complications
Query!
Assessment method [19]
0
0
Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
Query!
Timepoint [19]
0
0
Day 1 to Day 22
Query!
Secondary outcome [20]
0
0
Percentage of Participants With Adverse Events (AEs)
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
From first dose of study drug to Day 22
Query!
Eligibility
Key inclusion criteria
1. Patients or their legal guardians who provide written informed consent to participate
in the study on a voluntary basis. For adolescent patients, informed consent/assent of
voluntary participation should be obtained in accordance with local requirements.
2. Male or female patients = 12 years at the time of signing the informed consent/assent
form.
3. Patients with a diagnosis of influenza confirmed by all of the following:
1. Fever = 38ºC (axillary) during the predose examinations or within the 4 hours
prior if antipyretics were taken
2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a
negative RIDT may be enrolled if the patient reports contact with a known case of
influenza within the prior 7 days and all other inclusion criteria are met.
3. At least 1 each of the following general and respiratory symptoms associated with
influenza is present with a severity of moderate or greater:
i. General symptoms (headache, feverishness or chills, muscle or joint pain, or
fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
4. The time interval between the onset of symptoms and the predose examinations is 48
hours or less. The onset of symptoms is defined as either:
1. Time of the first increase in body temperature (an increase of at least 1ºC from
normal body temperature)
2. Time when the patient experiences at least 1 new general or respiratory symptom
5. If a women of childbearing potential, agrees to use a highly effective method of
contraception for 3 months after the first dose of study drug
6. Patients will be considered at high risk* of influenza complications due to the
presence of at least 1 of the following inclusion criteria:
1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or
cystic fibrosis)
2. Endocrine disorders (including diabetes mellitus)
3. Residents of long-term care facilities (eg, nursing homes)
4. Compromised immune system (including patients receiving corticosteroids not
exceeding 20 mg of prednisolone or equivalent, and patients being treated for
human immunodeficiency virus [HIV] infection with a CD4 count > 350 cells/mm³
within the last 6 months)
5. Neurological and neurodevelopmental disorders (including disorders of the brain,
spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure
disorders], stroke, muscular dystrophy, or spinal cord injury)
6. Heart disease (such as congenital heart disease, congestive heart failure, or
coronary artery disease), excluding hypertension without any other heart-related
symptoms
7. Adults aged = 65 years
8. American Indians and Alaskan Natives
9. Blood disorders (such as sickle cell disease)
10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial
disorders)
11. Morbid obesity (body mass index = 40 kg/m²)
12. Women who are within 2 weeks postpartum and are not breastfeeding
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patients with severe influenza virus infection requiring inpatient treatment.
2. Patients with known allergy to oseltamivir (Tamiflu®).
3. Patients unable to swallow tablets or capsules.
4. Patients who have previously received baloxavir marboxil.
5. Patients weighing = 40 kg.
6. Patients who have been exposed to an investigational drug within 30 days prior to the
predose examinations.
7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the
predose examinations. The following female patients who have documentation of either a
or b below do not need to undergo a pregnancy test at the predose examinations:
1. Postmenopausal women (defined as cessation of regular menstrual periods for 2
years or more and confirmed by a follicle-stimulating hormone test)
2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
tubal ligation
8. Patients with concurrent infections at the predose examinations requiring systemic
antimicrobial therapy.
9. Patients with liver disease associated with hepatic impairment.
10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below
350 cells/mm3 in the last 6 months.
12. Patients with immunosuppression following organ or bone marrow transplants.
13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic
corticosteroids.
14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
rimantadine, umifenovir or amantadine within 30 days prior to the predose
examinations.
15. Patients who have received an investigational monoclonal antibody for a viral disease
in the last year.
16. Patients with known creatinine clearance = 60 mL/min.
17. Patients who, in the opinion of the investigator, would be unlikely to comply with
required study visits, self-assessments, and interventions
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/01/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/04/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2184
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Shionogi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the efficacy of a single, oral dose of
baloxavir marboxil compared with placebo by measuring the time to improvement of influenza
symptoms in patients with influenza presenting within 48 hours of symptom onset.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02949011
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Shionogi Clinical Trials Administrator Clinical Support Help Line
Query!
Address
0
0
Shionogi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02949011
Download to PDF